How Diabetics Progress to Retina Complications

Video

A look at how primary care patients begin to present with diabetic retinopathy risk.

Eyes with moderate to severe nonproliferative diabetic retinopathy (NPDR) may be at the greatest risk of progression toward forms of diabetic retinopathy that result in blindness, according to findings from an analysis of screening data from US primary care centers.

In new research presented at the American Society of Retina Specialists (ASRS) 2020 Virtual Sessions this weekend, study author Geeta Lalwani, MD, of Boulder Community Health, reported that her team uncovered better interpretation of which patients with diabetes are most likely to advance toward more severe diabetic retinopathy.

Through an assessment of 22,000-plus diabetic patient eyes screened from 1999-2016, Lalwani and colleagues found that eyes with worsening diabetic retinopathy fall into 3 distinct clinical subtypes: progression to clinically-significant macular edema, proliferative diabetic retinopathy, and—in a small subset—progression to both.

“There almost seems like maybe there’s 3 separate populations—if we could go on to identify characteristics—who could go on to develop a subset of diabetic retinopathy,” Lalwani told HCPLive in an interview.

Additionally, Lalwani and colleagues found their findings were consistent with Early Treatment Diabetic Retinopathy Study DR Severity Scale (ETDRS-DRSS)—showing the value of a presently available metric for grading diabetic retinopathy patient risks, while complementing it with a better understanding of the paths these patients may go down.

To learn more about the study, watch HCPLive’s video interview with Lalwani above.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.